Clinical trials
Cell Therapy clinical trials
Below are recruiting cell therapy clinical trials, each written for real people, not researchers. We’re tracking 1,109 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07366658RecruitingPhase 1
Experimental therapy for neuroendocrine tumors that did not respond to treatment
This trial tests an experimental therapy (NEUK203-13) for people with neuroendocrine tumors, including small cell lung cancer, that have not responded to or stopped responding to standard treatments. It aims to see if the drug is safe and to look for early signs that it might shrink tumors, especially in people whose tumors have a specific marker called DLL3.
BeijingAges 18–75 - NCT02727803RecruitingPhase 2
Personalized natural killer cell therapy for blood cancers
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Houston, TexasAges 15–80 - NCT07223424RecruitingPhase 2
Patient preference study: shot vs infusion for immunotherapy
This study compares two ways to take immunotherapy drugs (nivolumab or pembrolizumab): as a shot under the skin (subcutaneous) versus an infusion into a vein (intravenous). It looks at which method patients prefer and is for people with certain advanced cancers where these drugs are already approved.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05639972RecruitingPhase 1/Phase 2
HPV cancer trial using immune T cells made for you
This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.
New Brunswick, New JerseyAges 18 years+ - NCT04481256Recruiting
Immunotherapy with chemoradiation for esophageal cancer
This trial tests adding medicines that block TGF-beta and PD-L1 to standard chemoradiation for esophageal squamous cell cancer that can’t be removed with surgery. It aims to improve control of the cancer where it sits, while keeping treatment safe.
AmsterdamAges 18 years+ - NCT06004336RecruitingPhase 2
Maintenance therapy after radiation for limited spread kidney cancer
This trial tests whether giving a maintenance medication (pembrolizumab) after targeted radiation helps keep kidney cancer that has spread to a few spots (5 or fewer) from growing. You would receive radiation to each spot and then be randomly assigned to receive either the medication or a placebo (inactive substance) for up to about 2 years.
Houston, TexasAges 18 years+ - NCT06733610RecruitingPhase 1
CAR T-cell therapy for AIHA after 3 failed treatments
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06346912RecruitingEarly Phase 1
CAR-T cell therapy for relapsed B-cell blood cancers
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
Hangzhou, ZhejiangAges 18 years+ - NCT04033302RecruitingPhase 1/Phase 2
Multi-CAR T cell therapy for CD7-positive blood cancers
This trial tests a new type of immune cell therapy (multi-CAR T cells) designed to target and kill cancer cells that have a marker called CD7. It may help people with certain blood cancers that have not responded well to other treatments.
Shenzhen, GuangdongAges 6 months–75 years - NCT05052528RecruitingPhase 1
CAR T cell therapy for relapsed or refractory large B-cell lymphoma
This trial tests whether adding a targeted antibody (rituximab) before CAR T cell therapy improves outcomes for patients with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments.
Sacramento, CaliforniaAges 18 years+ - NCT06343311RecruitingPhase 1/Phase 2
T-cell therapy for adults with relapsed or refractory B-cell lymphoma
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
Sacramento, CaliforniaAges 18 years+ - NCT07438067RecruitingPhase 1
EBV-targeted cell therapy after stem cell transplant
This trial tests a special immune cell therapy (EBV-AST) for people who have high levels of Epstein-Barr virus (EBV) in their blood after a stem cell transplant. The goal is to see if it can safely control the virus and prevent related complications.
BeijingAges 18–75 - NCT07070323RecruitingPhase 1/Phase 2
Nanobody CD5-CAR T cells for T-cell cancers
This trial tests a new treatment using your own or a donor's immune cells to fight certain T-cell cancers that haven't responded to standard therapies. It may help people who have few other options left.
Beijing, Beijing MunicipalityAges 1–70 - NCT06798298Recruiting
Long-term safety study of gene modified T cell treatment
This study is a long-term safety check for people who have already received a gene modified T cell treatment in a previous study sponsored by 2seventy bio or Regeneron Pharmaceuticals. The goal is to monitor your health for years after that treatment to see how well it works and if any side effects appear over time.
Nashville, TennesseeAges 18 years+ - NCT05437315RecruitingPhase 1/Phase 2
GD2/PSMA CAR-T therapy for hard-to-remove metastatic cancers
This early-phase study tests a custom immune-cell treatment (CAR-T) that targets two tumor markers called GD2 and PSMA. It may help people whose cancer is advanced, cannot be removed with surgery, and has the right marker pattern in their tumor tissue.
Shenzhen, GuangdongAges 1–75 - NCT04892433Recruiting
Tissue study for people getting CAR-T cell therapy
This study looks at tissue samples from adults who are receiving CAR-T cell therapy for blood-related conditions. It aims to learn more about how CAR-T works and what changes happen in the body, which may help improve future care.
Bologna, ItalyAges 18–70 - NCT07248163Recruiting
Universal CAR-T cell therapy for non-Hodgkin lymphoma
This trial tests a universal CAR-T cell therapy for patients with non-Hodgkin lymphoma whose cancer cells have CD19 on their surface. It might help if standard treatments have not worked.
ShanghaiAges 18 years+ - NCT03435796RecruitingPhase 2/Phase 3
Follow-up for people treated with gene-modified T cells
This study is a long-term check-in for people who previously received gene-modified T-cell infusions in a related Celgene/Juno/BMS trial. It helps researchers track safety and long-term effects over time.
Birmingham, AlabamaAges Any age - NCT05437328RecruitingPhase 1/Phase 2
CAR-T treatment for GD2/CD56 tumors that cannot be removed
This early-phase study tests a lab-made cell therapy (GD2/CD56 CAR-T) for cancers that have spread or come back and cannot be removed with surgery. It’s for people whose tumor tissue shows GD2 and/or CD56 on special lab tests, and it aims to control the cancer by targeting those tumor markers.
Shenzhen, GuangdongAges 1–75 - NCT05437341RecruitingPhase 1/Phase 2
CAR-T cell therapy for PSMA/CD70 tumors
This trial tests a lab-made immune cell treatment (CAR-T) designed to attack tumors that have specific markers called PSMA and/or CD70. It’s for people whose cancer has spread and can’t be fully removed with surgery, and it looks at safety and early signs of effectiveness.
Shenzhen, GuangdongAges 1–75 - NCT05438368RecruitingPhase 1/Phase 2
CAR-T therapy for tumors with GD2 or CD70 markers
This early-phase study tests a lab-made immune cell treatment (CAR-T) that targets tumor markers called GD2 and CD70. It is for people whose cancer has spread or returned and cannot be removed by surgery, to see if the treatment can work and how safe it is.
Shenzhen, GuangdongAges 1–75 - NCT07695012RecruitingEarly Phase 1
CAR-T cell therapy for B-cell acute lymphoblastic leukemia
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
RawalpindiAges 5–50 - NCT06613269RecruitingPhase 2
PET-guided radiation therapy for clear cell kidney cancer
This trial tests whether a special PET/CT scan (68Ga-NY104) can help guide radiation therapy for people with clear cell kidney cancer. The goal is to make radiation more precise and effective for treating tumors that haven't spread too much.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05887167RecruitingPhase 1
Test safety of making CAR T cells from your own blood
This Phase 1 study looks at whether it is safe and practical to collect your own stem cells and use them to support CAR T-cell therapy for certain blood cancers that have come back or did not respond. It aims to find the best way to combine these steps, which may help some people receive CAR T treatment.
Los Angeles, CaliforniaAges 18–85
Hear when a new Cell Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cell therapy?
- Yes. Clin2 currently lists 1,109 recruiting cell therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cell therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cell therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.